Categories: Health

Curadev Pharma Receives FDA ‘Study May Proceed’ Letter for its Investigational New Drug Application of CRD3874, an IV-Administered STING Agonist for the treatment of advanced/metastatic solid cancers

Published by
PRNW Agency

BOSTON, Mass. and NOIDA, India, Dec. 6, 2022 /PRNewswire/ — Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin a Phase 1 study of its lead STING agonist CRD3874 in advanced/metastatic solid cancers. The study will be performed at a leading US cancer center.

Successful clearance of tumors by the immune system requires the action of Type I IFNs. When activated in cells of the tumor microenvironment and lymph nodes, the immune adaptor protein STING coordinates proinflammatory immune responses by generating Type I IFNs and NF-κB activated cytokines. The human STING gene is polymorphic, with five major variants covering 98.8% of the population.

CRD3874 is a potent allosteric activator of all major human STING variants covering 98.8% of the population and is differentiated from the CDN class of STING agonists. CRD3874 displays strong T cell dependent anti-tumor activity when dosed through either the IV or IT routes in a range of syngeneic tumor models as a single agent or in combination with checkpoint inhibitors. As would be anticipated for an immune-modulated mechanism of action, mice that experienced complete tumor regression on treatment were refractory to challenge from re-engrafted tumor cells. 

“Immune evasion is an absolute requirement for the establishment of cancers. The systemic activation of STING by intravenous infusion of CRD3874-SI in patients with cancer is an attempt to re-activate dormant or disrupted immune mechanisms of tumor clearance,” says Dr. Arjun Surya, CEO & CSO of Curadev.

About Curadev:

Curadev is a small molecule drug discovery and development biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Programs at Curadev seek to ameliorate disease by translating cutting edge discoveries into new medicines. To know more about Curadev, visit our website

For enquiries:

Manish Tandon,
Co-Founder & CFO



PRNW Agency

Recent Posts

Metro Supply Chain partners with the Arrows to support

TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Metro Supply Chain Inc., a leading provider of… Read More

24 mins ago

Innofactor Plc: Share Repurchase 27.1.2023

January 27, 2023 11:30 ET | Source: Innofactor Plc Innofactor Plc Espoo, FINLAND English Finnish… Read More

37 mins ago

Extraordinary General Meeting of February 15, 2023: Notice

Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents Paris,… Read More

39 mins ago

DAS Technology Unveils Groundbreaking CX Automotive Mystery Shop Study at NADA 2023

Leading Customer Data and Experience Platform (CDXP) technology company unveils insights from 1,850 auto dealership… Read More

40 mins ago

Visteon to Announce Fourth Quarter and Full-Year 2022

VAN BUREN TOWNSHIP, Mich., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Visteon Corporation (Nasdaq: VC), a… Read More

2 hours ago

Savista Receives HFMA Peer Review Designation

CHICAGO, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) recently reviewed… Read More

2 hours ago